Accreditation Information

Accreditation
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (UAN 0245-0000-16-003-L01-P).

Nursing (ANCC)
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CE request form, statements of credit for physicians and nurses will be issued via email within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy®(NABP®) CPE Monitor electronic CE tracking system.

Needs Statement

Lung cancer is the most common cancer worldwide as well as the leading cause of cancer-related mortality.1 Of all the subtypes, non-small cell lung cancer (NSCLC) is the most common, comprising 85% of lung cancers.2,3 Despite the diagnostic and therapeutic advancements, NSCLC prognosis remains grim, with only 17.4% of patients surviving five years past diagnosis.4 Recently, there has been a rapid expansion of our knowledge regarding the molecular pathology of NSCLC that has led to the development of targeted therapies, including those targeting epidermal growth factor receptor (EGFR) mutations -- one of the most frequent “actionable” alterations in NSCLC.5,6 With these advancements and expanded treatment options, including the recent FDA approval of the third-generation EGFR tyrosine kinase inhibitor (TKI), new clinical algorithms that take into account individual patient molecular and clinical profiles are needed.

The National Comprehensive Cancer Network and the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology have recently published guidelines and a consensus statement regarding key pathologic, diagnostic, and therapeutic considerations, including optimal choice of EGFR TKI, the role of repeat biopsies, and use of circulating free DNA.7,8,9 Thus, it is imperative for clinicians to stay up-to-date and understand the molecular pathology of NSCLC, when molecular testing is appropriate, and how to interpret test results to guide therapy. Due to this rapidly evolving nature of NSCLC treatment paradigm, all of the members of the oncology team must be knowledgeable about the safety and efficacy of current and emerging NSCLC therapies.

References
1Ferlay J, et al. Int J Cancer. 2015. 2Ettinger DS, et al. J Natl Compr Canc Netw. 2012. 3George J, et al. Nature. 2015. 4National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/lungb/html. 5Cancer Genome Atlas Research. Nature. 2014. 6Berge EM, et al. Semin Oncol. 2014. 7National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. 8Lindeman NI, et al. J Mol Diagn. 2013. 9Tan DS, et al. J Thorac Onco. 2016.

Objectives

At the conclusion of this application-based activity, participants will be able to:

  • Review the molecular pathology of advanced lung cancer and examine its relevance for clinical practice.
  • Appraise the safety and efficacy of first-line therapies for advanced NSCLC, including chemotherapy and 1st and 2nd generation EGFR TKIs.
  • Evaluate treatment approaches used to overcome EGFR resistance in advanced NSCLC, including the safety and efficacy of second- and third-line therapies.
  • Differentiate recommended molecular testing and role for ctDNA in detecting EGFR mutations, including T790M.

Target Audience

Hospital-based clinicians involved in the care of patients with non-small cell lung cancer (NSCLC) including oncologists, oncology residents/fellows, oncology specialty nurse practitioners, nurses, nurse navigators, physician assistants, and pharmacists.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in educational presentations. Relevant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Joan B. Fowler, PharmD, BCPP – has no relevant financial relationships to disclose in relation to the content of this activity.

Adrienne Matson, PharmD, BCPS – has no relevant financial relationships to disclose in relation to the content of this activity.

Rinata Simien NP-C – has no relevant financial relationships to disclose in relation to the content of this activity.

Melissa Wilson, MD – has disclosed that she is a consultant for Bristol-Myers Squibb.

Authors/Presenters:
Sanjiv S. Agarwala, MD – has no relevant financial relationships to disclose in relation to the content of this activity.

Robert H.I. Andtbacka, MD, CM, FACS, FRCSC – has disclosed that he is a consultant for Amgen and Merck.

Michael B. Atkins, MD – has disclosed that he is a consultant for Bristol-Myers Squibb, Genetech, Merck, Necktar, Novartis, and Pfizer.

Edward B. Garon, MD, MS – has disclosed that he receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, Novartis, and Pfizer.

David Gerber, MD - has disclosed he has received research funding from ArQule, Boehringer-Ingelheim, BerGenBio, Celgene, Genentech, ImmunoGen, Karyopharm, and Peregrine. He has also participated on advisory boards for Boehringer-Ingelheim, Bristol Myers-Squibb Company, MS, Celgene, Genentech, Guardant, Peregrine, Samsung, Synta, and AstraZeneca.

Roy S. Herbst, MD, PhD – has disclosed that is a consultant for Lilly, Genentech/Roche, Merck, and Pfizer; receives grant/research support from Genentech; and is a member of the scientific advisory boards for Biothera, Diatech, and Kolltan.

Suzanne McGettigan, MSN, CRNP, AOCN® - has disclosed that she is a member of the speakers’ bureaus for Bristol-Myers Squibb, Genentech, Merck, and Novartis.

Michael A. Postow, MD – has disclosed that he is a consultant for Amgen and Bristol-Myers Squibb. He also receives grant/research support from Bristol-Myers Squibb and Novartis.

Brian I. Rini, MD, FACP – has disclosed that he is a consultant for Acceleron, Novartis, Pfizer, and Roche. He also receives grant/research support from Acceleron, Bristol-Myers Squibb, Peloton, Pfizer, and Roche.

Naiyer Rizvi, MD – has disclosed that he is a consultant for AstraZeneca, Merck, Novartis, and Roche. He is also a shareholder/co-founder of Gritstone Oncology.

Sumit K. Subudhi, MD, PhD – has disclosed that he is a member of the speakers’ bureaus for Dendreon and Valeant Pharmacetuicals.

VanAnh Thuy Trinh, PharmD, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.

Jeffrey S. Weber, MD, PhD – has disclosed that he is a consultant for AbbVie, Altor, AstraZeneca, Bristol-Myers Squibb, cCAM, Celldex, CytoMx, EMD Serono, Genentech/Roche, GlaxoSmithKline, Merck, and Nektar. He also receives grant/research support from Altor, cCAM, Celldex, and CytoMx.